We are live on ! Find out more
ARCKW

Arbor Rapha Capital Bioholdings Corp. I Warrants
ARCKW

Delisted

ARCKW was delisted on the 10th of January, 2023.

1 hedge funds and large institutions have $0 invested in Arbor Rapha Capital Bioholdings Corp. I Warrants in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 431 (-42)

100% less capital invested

Capital invested by funds: $2.33M → $0 (-$2.33M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 42

Holders
1
Holders Change
-42
Holders Change %
-97.67%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
42
Calls
Puts
Net Calls
Net Calls Change

ARCKW Hedge Fund Activity: Q1 2023 in Review

1 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Arbor Rapha Capital Bioholdings Corp. I Warrants (ARCKW) for Q1 2023, worth a combined $0 — down 100% from $2.33M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of ARCKW and 0 opened new positions — a net loss of 42 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $1.08M sold.

  • 1 institutional investor held Arbor Rapha Capital Bioholdings Corp. I Warrants (ARCKW) as of Q1 2023, down from 43 in Q4 2022.
  • Funds reported $0 of Arbor Rapha Capital Bioholdings Corp. I Warrants stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Arbor Rapha Capital Bioholdings Corp. I Warrants positions in Q1 2023 and 42 closed out, a net change of -42 holders.
  • The largest Arbor Rapha Capital Bioholdings Corp. I Warrants seller in Q1 2023 was Radcliffe Capital Management, an estimated $1.08M sold.

Based on aggregated 13F filings for Q1 2023.